Synchrony Financial Aktie - SFE

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

45,27

Gebot

44,995

Fragen

45,54

Volumen

1.078

45,48 Tagesbereich 45,505

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

17,599B

Handelsende

45,61

Handelsbeginn

45,505

Letzte Trade

45.48

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

388.749.489

Dividendenrendite

Kurs-Gewinn-Verhältnis

5,83

Gewinn pro Aktie (EPS)

8,82

Erlöse

16,13B

Nettogewinn

3,43B

Sektor

Finance Services

Branche

Finance Services

Website

www.synchrony.com

Hauptsitz

Stamford, Connecticut, USA

Gegründet

Synchrony Financial is listed in the Finance Services sector of the Tradegate (DE) with ticker SFE. The last closing price for Synchrony Financial was 45,61 €. Over the last year, Synchrony Financial shares have traded in a share price range of 0,00 € to 0,00 €.

Synchrony Financial currently has 388.749.489 shares in issue. The market capitalisation of Synchrony Financial is 17,73 € billion. Synchrony Financial has a price to earnings ratio (PE ratio) of 5.83.

MDB Capital Group Announces 'Best and Brightest' List of Qualifying Companies for 1st Annual Bright Lights Conference in San Fra

Bright Lights Conference Will Showcase 50 of the Most Innovative U.S. Small Cap Companies with Disruptive Intellectual Property in San Francisco...

Molecular Biometrics Closes $12.5 Million Series B Equity Funding

NORWOOD, Mass., Jan. 12 /PRNewswire/ -- Molecular Biometrics®, Inc., a metabolomics company developing novel clinical diagnostic tools for...

Clarient Reports 41% Revenue Increase for First Quarter 2009

New Molecular Tests and Increased Case Volume Continue to Drive Revenue Growth ALISO VIEJO, Calif., May 6 /PRNewswire-FirstCall/ -- Clarient...

Clarient Launches New Breast Cancer Test

The Clarient Insight(R) Dx Breast Cancer Profile Assists Physicians In Identifying Recurrence Risk and the Need for Chemotherapy ALISO VIEJO...

Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corpor

FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast cancer patients; Further strengthens Company's...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

SFE - Frequently Asked Questions (FAQ)

What is the current Synchrony Financial share price?

The current share price of Synchrony Financial is 45,27 €

How many Synchrony Financial shares are in issue?

Synchrony Financial has 388.749.489 shares in issue

What is the market cap of Synchrony Financial?

The market capitalisation of Synchrony Financial is EUR 17,73B

What is the 1 year trading range for Synchrony Financial share price?

Synchrony Financial has traded in the range of 0,00 € to 0,00 € during the past year

What is the PE ratio of Synchrony Financial?

The price to earnings ratio of Synchrony Financial is 5,83

What is the cash to sales ratio of Synchrony Financial?

The cash to sales ratio of Synchrony Financial is 1,24

What is the reporting currency for Synchrony Financial?

Synchrony Financial reports financial results in USD

What is the latest annual turnover for Synchrony Financial?

The latest annual turnover of Synchrony Financial is USD 16,13B

What is the latest annual profit for Synchrony Financial?

The latest annual profit of Synchrony Financial is USD 3,43B

What is the registered address of Synchrony Financial?

The registered address for Synchrony Financial is CORPORATION TRUST CENTER, 1209 ORANGE ST, STAMFORD, CONNECTICUT, 19801

What is the Synchrony Financial website address?

The website address for Synchrony Financial is www.synchrony.com

Which industry sector does Synchrony Financial operate in?

Synchrony Financial operates in the FINANCE SERVICES sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WW6Ww International Inc	0,3468 € (169,88%)	144,1k
OYM1Odyssey Marine Exploration Inc	1,39 € (82,89%)	120,38k
VW5Cannabist Company Holdings Inc	0,0643 € (78,61%)	153,41k
Z620Trillion Energy International Inc	0,0307 € (48,31%)	103,45k
K8DWellfield Technologies Inc	0,0142 € (47,92%)	500
A07Avance Gas Holding Ltd	0,27 € (-46,80%)	1,26M
3SHShunfeng International Clean Energy Limited	0,0014 € (-36,36%)	3k
SQRSaia Inc.	216,00 € (-30,77%)	528
L7C2Windfall Geotek Inc	0,008 € (-30,43%)	32,29k
3PJ1Golden Dory Resourses	0,02 € (-25,93%)	40k
DMLSayona Mining Limited	0,0113 € (4,63%)	2,52M
11LCanopy Growth Corporation	1,222 € (-6,86%)	2,31M
PF8European Lithium Limited	0,0314 € (3,29%)	2,18M
D7GNel ASA	0,1982 € (-1,49%)	2,15M
3CPXiaomi Corporation	5,459 € (-1,83%)	1,56M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Synchrony Financial (SFE)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Synchrony Financial

SFE Neueste Nachrichten

MDB Capital Group Announces 'Best and Brightest' List of Qualifying Companies for 1st Annual Bright Lights Conference in San Fra

Molecular Biometrics Closes $12.5 Million Series B Equity Funding

Clarient Reports 41% Revenue Increase for First Quarter 2009

Clarient Launches New Breast Cancer Test

Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corpor

Clarient to Present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17th

Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008

Laureate Pharma Appoints Gary Swan as Vice President of Operations

Laureate Pharma Extends Lease for its Facility in Princeton, NJ

EDGAR(R) Online, Inc. Announces Appointment of Philip Moyer as President

SFE - Frequently Asked Questions (FAQ)

Beweger

SFE Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Synchrony Financial (SFE) Börsenkurse

Synchrony Financial (SFE)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Synchrony Financial

SFE Neueste Nachrichten

MDB Capital Group Announces 'Best and Brightest' List of Qualifying Companies for 1st Annual Bright Lights Conference in San Fra

Molecular Biometrics Closes $12.5 Million Series B Equity Funding

Clarient Reports 41% Revenue Increase for First Quarter 2009

Clarient Launches New Breast Cancer Test

Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corpor

Clarient to Present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17th

Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008

Laureate Pharma Appoints Gary Swan as Vice President of Operations

Laureate Pharma Extends Lease for its Facility in Princeton, NJ

EDGAR(R) Online, Inc. Announces Appointment of Philip Moyer as President

SFE - Frequently Asked Questions (FAQ)

Beweger

SFE Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE